创新药物研发投入激励法律制度实施效果的国际比较分析  

International comparison on implemented effect of the law system aimed to incentive the input of innovative drug R&D

作　　者：杨军歌[1] 丁锦希[1] 邵蓉[1] 

机构地区：[1]中国药科大学国际医药商学院,江苏南京211198

出　　处：《中国医药导报》2011年第4期6-8,26,共4页China Medical Herald

基　　金：国家社会科学基金项目名称<创新药物研发科技投入与激励法律制度研究>;项目编号:10CFX055;国家知识产权局软课题项目名称<创新药物研发的知识产权激励和保护政策研究>;项目编号:SS09-A-26

摘　　要：为完善我国创新药物研发投入激励法律制度提供建议,建立创新药物研发投入激励法律制度及其实施效果评价指标体系,并选取创新药物研发水平较高国家的相关指标进行对比分析。结果显示,我国的财税相关政策、科技人才激励政策等在激励创新药物研发方面还有待进一步完善。我国创新药物研发水平与国外发达国家相比还存在较大差距,调整相关激励政策是激励创新药物研发投入,继而提高其产出的重要保证。To provide suggestions to complete the law system aimed to incentive the input of innovative drug RD in China,we established an appraisal system aiming at evaluating the implemented effect of the law above and sample related indexes of the countries whose innovative drug RD was relatively developed as comparison objects.Results showed that,tax and financial related law and talent-stimulation law system which were set to stimulate innovative drug RD in China needed to be better perfected.The gap of innovative drug RD level between China and the developed countries is large,while adjusting related incentive law is the main guarantee to stimulate the RD input and output.

关 键 词：创新药物研发 投入激励法律制度 实施效果国际比较 

分 类 号：Q81[生物学—生物工程]